BeOne Medicines (ONC) EBITDA Margin (2015 - 2026)
BeOne Medicines' (ONC) quarterly EBITDA Margin came in at 16.51% in Q1 2026, up 1552.0% year-on-year from 1.0% in Q1 2025, and up 33.69% on a QoQ basis from 12.35% in Q4 2025.
BeOne Medicines (ONC) EBITDA Margin (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has 12 years of EBITDA Margin data on file, last reported at 16.51% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 1552.0% year-over-year to 16.51% in Q1 2026; TTM through Mar 2026 was 11.95%, a 1903.0% increase from a year earlier, with the FY2025 full-year figure at 8.37%, up 2328.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 16.51%, up from 12.35% in the prior quarter.
- Over the last five years, EBITDA Margin for ONC reached as high as 16.51% in Q1 2026 and fell as low as 144.57% in Q1 2022.
- Historically, EBITDA Margin has averaged 43.58% across 5 years, with a median of 17.15% in 2023.
- On a YoY basis, EBITDA Margin climbed as much as 18794 bps in 2022 and fell as far as 21235 bps in 2022.
- Year by year, EBITDA Margin stood at 123.29% in 2022, then jumped by 51 bps to 60.5% in 2023, then jumped by 88 bps to 7.04% in 2024, then jumped by 275 bps to 12.35% in 2025, then surged by 34 bps to 16.51% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 16.51% in Q1 2026, 12.35% in Q4 2025, and 11.55% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 23.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.51% |
| Dec 31, 2025 | 12.35% |
| Sep 30, 2025 | 11.55% |
| Jun 30, 2025 | 6.68% |
| Mar 31, 2025 | 0.99% |
| Dec 31, 2024 | -7.04% |
| Sep 30, 2024 | -12.01% |
| Jun 30, 2024 | -11.53% |
| Mar 31, 2024 | -34.77% |
| Dec 31, 2023 | -60.50% |
| Sep 30, 2023 | -17.15% |
| Jun 30, 2023 | -53.54% |
| Mar 31, 2023 | -82.91% |
| Dec 31, 2022 | -123.29% |
| Sep 30, 2022 | -113.09% |
| Jun 30, 2022 | -128.64% |
| Mar 31, 2022 | -144.57% |
| Dec 31, 2021 | 89.06% |
| Sep 30, 2021 | -223.95% |
| Jun 30, 2021 | -316.58% |